Even as the bears are running wild on the street causing across-the-board damage, there are sectors that have kept them at bay. And that’s ...

Let’s accept the fact that we are likely to be dealing with volatility for the next four years. Both in the real world and in the global an...

The relationship between a decline in the rupee and better margins for IT companies is well known. What is not discussed much is that pharm...

Every now and then the market goes through phases, where it prefers a certain set of stocks, not based on sector but based on the overall m...

Both at the real business condition and on the valuation cycle on the street. The Indian pharmaceutical sector has undergone significant ch...

For the next couple of weeks, what will dominate the narrative on the street would be the action and expectation from the US Fed and Iran’s...

In the last two months of the market, while the midcaps have done well, though the pace at which the outperformance was taking place has sl...

In a market where bulls are ruling every corner of the street, and stocks are either fairly valued or overvalued. The big question is how d...

It is not very common to see tailwinds emerging for an industry at a time when it is ideal to own stocks from that space. But in the case o...

After a long period of under performance, pharma stocks have seen interest coming back from institutional investors. This is because some t...

Pharma stocks had been underperforming for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets h...

As India battles to vaccinate its population, private players will prove to be critical in meeting the inoculation targets.

The expansion is planned to be ready for customers beginning summer 2022. It is expected that the expansion will add around twenty new hire...

The stock was the top gainer on Nifty Pharma index on Wednesday and was among the top gainers in the Nifty Midcap 100 pack.

"Ash Stevens will add high potency capabilities to the services we offer our customers," Vivek Sharma, Pharma Solutions business CEO, Piram...

Dishman Pharmaceuticals Ltd, will now focus on the high-potency therapies like steroids, hormones, isotopes and cytotoxics.

Dishman will acquire the fine chemicals, vitamin D and vitamin D analogues business of Solvay Pharma.